Memphasys Ltd · ASX:MEM
Memphasys — Investor Presentation (May 2022)
29 slides from Memphasys's investor presentation, May 2022
Slide 1: Creating high value product portfolio targeting the growing fertility industry
Creating high value product portfolio targeting the growing fertility industry Alison Coutts CEO & Managing Director, Memphasys Limited. May 2022 1
Slide 2: Disclaimer
Disclaimer This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on informat
Slide 3: Memphasys (ASX: MEM) Investment Proposition
Memphasys (ASX: MEM) Investment Proposition § A MedTech company focused on reproductive biotechnology Distinguished Laureate Professor John § Developing world class product portfolio (devices, Aitken, global leader in reproductive diagnostics and media products) addressing major biology: human and a
Slide 4: Board & management with strong commercialisation experience
Board & management with strong commercialisation experience - A highly strategic and results focused private health care leader with 40+ year career in the health industry. - Experience spans executive leadership of publicly listed and privately owned healthcare companies, overseeing numerous M&A tr
Slide 5: Board & management with strong commercialisation experience
Board & management with strong commercialisation experience - Long established track-record in the medical technology industry Ross Harricks - Specialised in assisting companies through the commercialisation process, having worked with and been on boards Business of ResMed, Cardiex, VentraCor and Pa
Slide 6: Highly Prospective Core Product Development Pipeline
Highly Prospective Core Product Development Pipeline Prototyping Development of Clinical Trials & Product Development Program Proof of Concept Prototype UoN lab Go-to-Market Regulatory Market Launch Field trial Product Filings Development Validation 1. Felix™ Device Regulated Regulated Regulated mar
Slide 7: MEM's First Commercial Product: Felix Device
MEM’s First Commercial Product: Felix™ Device § A patented, rapid, automated device used in human IVF procedures § Selects quality sperm based on negative charge and size § Less DNA damage than processes using centrifugation (e.g. DGC, most prevalent method) § Uses gentle electric forces to safely a
Slide 8: Felix Device - How it works
Felix™ Device - How it works Allows ion transfer but blocks sperm passage Raw Semen Processed Semen Mature, negatively charged sperm harvested Separates sperm from other cell types after 6 minutes 8
Slide 9: Felix Device - Advantages over current processes
Felix™ Device - Advantages over current processes Current sperm separation processes used for IVF § DGC (density gradient centrifugation) and Swim up* § Cost at least ~A$80 (for each technique) per cycle § DGC is more frequently used Felix™ Device Current processes One step, automated Each involves
Slide 10: Felix Device - Potential Market Size
Felix™ Device - Potential Market Size Fresh IVF Cycles § IVF global use is accelerating, but IVF’s success rate remains stubbornly low 5 (Millions) Fresh IVF Cycles (millions) § Aust. and NZ pregnancy rate per cycle is only 16.5% with fresh embryos 4 3.54 3.9 3.28 implanted (58% of cycles) but 28% w
Slide 11: Felix Device - Pathway to Market
Felix™ Device - Pathway to Market § Key Opinion Leaders (KOLs) are the esteemed practitioners the wider IVF sector looks to for innovation & leadership § KOLs in 13 IVF clinics in 8 countries are completing in vitro assessments of FelixTM Device with results due in 2Q 2022 § KOL clinics are the like
Slide 12: Felix Device - Commercialisation path
Felix™ Device - Commercialisation path Early Markets Regulated Markets § KOLs in place in all 4 early markets § Commercialisation activities in more regulated markets § Pathfinder repeat sales achieved in India; more expected (Australia, USA, China and EU) require formal clinical § Embryo quality as
Slide 13: 2. ROSA (Rapid Oxidative Stress Assay)
2. ROSA (Rapid Oxidative Stress Assay) § Oxidative stress is an imbalance between reactive oxygen species and antioxidant protection within the body § This imbalance increases with age Antioxidants from: Cellular External Adverse and can lead to serious diseases Cellular reactions Healthy diet Metab
Slide 14: ROSA - Clear need for a diagnostic device
ROSA - Clear need for a diagnostic device § For males, oxidative stress in the sperm is a major contributor to infertility § There is no simple oxidative stress clinical assessment; complex lab tests are required and therefore not often used § Oxidative stress is important to treat correctly Antioxi
Slide 15: ROSA - Major market opportunity
ROSA - Major market opportunity >1.5m US males 25-44 yrs old visited doctor’s office p.a. for detailed semen Potential to also add females assessment1 Total addressable suspected of suffering from market: oxidative stress > 15 million men The global antioxidants market size was Accessible valued at
Slide 16: ROSA - Development pathway
ROSA - Development pathway § The diagnostic will utilise a novel biochemistry-based assay § Biochemistry optimisation and validation process underway § Early proof of concept achieved § Conceptual device design process commenced § Ability to develop a technically and commercially robust biochemical
Slide 17: 3. Samson Device
3. SamsonTM Device A device used in the breeding shed to provide a pregnancy prediction within an hour after a stallion-mare mating, for both thoroughbreds and horses bred by artificial insemination (AI) § Early pregnancy within the breeding season is a major financial advantage to breeders § Racing
Slide 18: Samson Device - Value proposition
SamsonTM Device - Value proposition Thoroughbreds Horses breed by AI (Bred naturally) All other horses Thoroughbreds for racing Horse type eg standardbreds (trotters), quarter horses, Australian stock (Not allowed to be bred by AI) horses, Arabians, polo ponies, warm bloods etc Australia Australia U
Slide 19: Samson Device - Progress & Next Steps
SamsonTM Device - Progress & Next Steps § Proof of concept field trial completed in 2021 breeding season for thoroughbreds and standardbreds § The SamsonTM Device initial prediction algorithm ~90% accurate in standardbreds § If thoroughbred algorithm optimised for individual stallions, pregnancy pre
Slide 20: 4. SemPort
4. SemPort A human semen transport system to prevent degradation of the sperm for ~3 days to enable a full, accurate semen analysis to be remotely provided on intact semen held at ambient temperature. The Problem: The Solution: § Sperm do not freeze well and keeping in seminal plasma § Customer will
Slide 21: SemPort: How it will be used
SemPort: How it will be used ~3 days to keep sample viable for accurate analysis. Currently sperm survive <24 hours and many die in that time frame. Specialised Donor provides analytical lab semen sample Referring Specialised receives at nominated Semen clinician will Medical SemPort Analytical lab
Slide 22: SemPort - Product development
SemPort - Product development Development path: Potential accessible market size: § Early proof of concept achieved for proprietary long-life semen ~1 million men pa medium and transport device. Optimisation work proceeding § Prototype system (medium and device) to be made, ready for clinical testin
Slide 23: 5. AI-Port
5. AI-Port Device to store and transport semen for Artificial Insemination (AI) without freezing Global Animal AI market, by species. Total market size: US$4.2Billion; § The global AI market is large and extensively used in cattle, pigs, sheep and horses 10 year CAGR 6.5% § Semen for AI is usually f
Slide 24: 5. AI-Port use Vs. traditional method
5. AI-Port use Vs. traditional method AI-Port benefits (from using fresh semen) Traditional Method • Likely to improve AI success rates • Would enable semen straws to be loaded with less but more reproductively viable sperm Sample collected Laboratory assessment Addition of semen Straws loaded with
Slide 25: Memphasys Investment Highlights
Memphasys Investment Highlights § Addressing major global human and animal reproductive markets § First commercial sales of FelixTM Device § Expanding portfolio of new products to meet unfulfilled reproductive market needs in humans and in high-value animals § Board & management with strong strategi
Slide 26: Corporate Snapshot
Corporate Snapshot MEM 12mth Share Price ASX Code MEM Share price (as at 14/02/22) $0.063 Shares on issue 792.18 million Market capitalisation ~$50 million Cash & Cash Equivalents ~$1.95 million (as at 31 Dec 21) Peters Investments Ownership structure – (27.2%) substantial shareholders Mr Andrew (as
Slide 27: Board of Directors
Board of Directors More than 40 years in healthcare, spanning executive leadership of publicly listed and privately owned healthcare companies, overseeing Robert Cooke numerous M&A transactions and management of private and public hospitals in Australia, Asia and the UK. Non-Executive MD & CEO of He
Slide 28: Appendix 1: Patents & Trademarks
Appendix 1 : Patents & Trademarks Patents Granted For FelixTM Device Country Patent Title Expiry US Cell Separation Jul 26 US Biocompatible Polymeric Membranes Aug 37 China Sperm separation by electrophoresis Oct 37 US Sperm separation by electrophoresis Oct 37 Australia Sperm cell separation by ele
Slide 29: Appendix 2: Importance of sperm's negative charge
Appendix 2: Importance of sperm’s negative charge § During sperm maturation, the sperm head is covered by a glycoprotein and glycolipid coating which has a highly negative electric charge § Negative charge has been correlated with: § Normal morphology (shape) § Lower levels of DNA fragmentation § Th